HRP20200876T1 - Modulatori nuklearnog transporta i njihove uporabe - Google Patents

Modulatori nuklearnog transporta i njihove uporabe Download PDF

Info

Publication number
HRP20200876T1
HRP20200876T1 HRP20200876TT HRP20200876T HRP20200876T1 HR P20200876 T1 HRP20200876 T1 HR P20200876T1 HR P20200876T T HRP20200876T T HR P20200876TT HR P20200876 T HRP20200876 T HR P20200876T HR P20200876 T1 HRP20200876 T1 HR P20200876T1
Authority
HR
Croatia
Prior art keywords
virus
compound
alkyl
disorder
solvate
Prior art date
Application number
HRP20200876TT
Other languages
English (en)
Inventor
Vincent P. Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200876(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of HRP20200876T1 publication Critical patent/HRP20200876T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

1. Spoj formule I: [image] ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat, pri čemu: R1 je odabran od vodika i C1-C4 alkila; R2 je O; i R3 je odabran od -N(R4)-(C3-C6 cikloalkila), -C1-C6 alkila, -(C0-C4 alkilen)-heterociklila, i -(C0-C4 alkilen)-heteroarila, pri čemu bilo koji alkil, alkilen, heterociklil i heteroaril dio od R3 je izborno i neovisno supstituiran; i R4 je odabran od vodika i C1-C4 alkila.
2. Spoj, sol, solvat ili hidrat prema zahtjevu 1, pri čemu: R1 je vodik; i R3 je odabran od -N(R4)-(C3-C6 cikloalkila), -C3-C6 alkila, -(C0-C1 alkilen)-heterociklila, i -(C0-C1 alkilen)-heteroarila, pri čemu: bilo koji alkil ili alkilen dio od R3 je izborno i neovisno supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od okso i -N(R5)2, pri čemu svaki R5 je neovisno odabran od vodika i C1-C4 alkila; bilo koji heterociklil dio od R3 sadrži barem jedan atom dušika u prstenu, i izborno je supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od C1-C4 alkila i okso; i bilo koji heteroaril dio od R3 sadrži barem jedan atom dušika u prstenu i izborno je supstituiran s jednim ili više C1-C4 alkila.
3. Spoj, sol, solvat ili hidrat prema zahtjevu 1, pri čemu: bilo koji heteroaril dio od R3 je izborno i neovisno supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od -OH, -SH, nitro, halogena, amino, cijano, C1-C12 alkila, C2-C12 alkenila, C2-C12 alkinil skupine, C1-C12 alkoksi, C1-C12 haloalkila, C1-C12 haloalkoksi i C1-C12 alkil sulfanila; i bilo koji alkil, alkilen, ili heterociklil dio od R3 je izborno i neovisno supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od okso, -OH, -SH, nitro, halogena, amino, cijano, C1-C12 alkila, C2-C12 alkenila, C2-C12 alkinila, C1-C12 alkoksi, C1-C12 haloalkila, C1-C12 haloalkoksi i C1-C12 alkil sulfanila.
4. Spoj prema zahtjevu 1 predstavljen bilo kojom od strukturnih formula navedenih ispod: [image] ili [image] ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat.
5. Spoj prema zahtjevu 4 predstavljen sljedećom strukturnom formulom: [image] ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat.
6. Spoj prema zahtjevu 4 predstavljen sljedećom strukturnom formulom: [image] ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat.
7. Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1-6, ili njegovu farmaceutski prihvatljivu sol, solvat ili hidrat, i farmaceutski prihvatljiv nosač.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat, ili farmaceutski sastav prema zahtjevu 7 za uporabu u liječenju poremećaja odabranog od proliferativnog poremećaja, upalnog poremećaja, autoimunog poremećaja, virusne infekcije, oftamološkog poremećaja, neurodegenerativnog poremećaja, poremećaja abnormalnog rasta tkiva, poremećaja vezanog uz unos hrane, alergija i poremećaja disanja.
9. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8, pri čemu je poremećaj odabran od lupusa, multiple skleroze i amiotrofične lateralne skleroze.
10. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je lupus.
11. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je multipla skleroza.
12. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je amiotrofična lateralna skleroza.
13. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8, pri čemu se spoj primjenjuje u kombinaciji s dodatnim terapijskim agensom.
14. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8, pri čemu poremećaj je neurodegenerativna bolest odabrana od Parkinsonove bolesti, Alzheimerove bolesti i Huntingtonove bolesti.
15. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8, pri čemu je poremećaj virusna infekcija uzrokovana virusnim patogenom odabranim od adenovirusa, koksaki virusa, denga virusa, virusa encefalitisa, Epstein-Barr virusa, virusa hepatitisa A, virusa hepatitisa B, virusa hepatitisa C, herpes simpleks virusa tipa 1, herpes simpleks virusa tipa 2, citomegalovirusa, humanog herpes virusa tipa 8, virusa humane imunodeficijencije, virusa gripe, virusa ospica, virusa zaušnjaka, humanog papilomavirusa, virusa parainfluence, poliovirusa, virusa bjesnoće, respiratornog sincicijskog virusa, virusa rubele, varicella-zoster virusa, virusa zapadnog Nila, dungee i virusa žute groznice.
HRP20200876TT 2012-05-09 2020-06-02 Modulatori nuklearnog transporta i njihove uporabe HRP20200876T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15
EP18164757.9A EP3404027B1 (en) 2012-05-09 2013-05-09 Nuclear transport modulators and uses thereof

Publications (1)

Publication Number Publication Date
HRP20200876T1 true HRP20200876T1 (hr) 2020-09-04

Family

ID=49448240

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20181838TT HRP20181838T1 (hr) 2012-05-09 2018-11-06 Modulatori nuklearnog transporta i njihove uporabe
HRP20200876TT HRP20200876T1 (hr) 2012-05-09 2020-06-02 Modulatori nuklearnog transporta i njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20181838TT HRP20181838T1 (hr) 2012-05-09 2018-11-06 Modulatori nuklearnog transporta i njihove uporabe

Country Status (32)

Country Link
US (10) US9266843B2 (hr)
EP (3) EP3663291A1 (hr)
JP (5) JP6195909B2 (hr)
KR (5) KR102163377B1 (hr)
CN (1) CN104428295B (hr)
AU (5) AU2013259384B2 (hr)
BR (1) BR112014027860B8 (hr)
CA (1) CA2872190A1 (hr)
CL (1) CL2014003054A1 (hr)
CO (1) CO7190242A2 (hr)
CY (2) CY1120832T1 (hr)
DK (2) DK3404027T3 (hr)
EA (1) EA036639B1 (hr)
ES (2) ES2794866T3 (hr)
GE (1) GEP20237477B (hr)
HK (1) HK1209420A1 (hr)
HR (2) HRP20181838T1 (hr)
HU (2) HUE040427T2 (hr)
IN (1) IN2014DN09434A (hr)
LT (2) LT2858991T (hr)
ME (1) ME03795B (hr)
MX (1) MX364992B (hr)
NZ (1) NZ702663A (hr)
PE (1) PE20150128A1 (hr)
PL (2) PL3404027T3 (hr)
PT (2) PT2858991T (hr)
RS (2) RS60424B1 (hr)
SG (1) SG11201407268SA (hr)
SI (2) SI3404027T1 (hr)
UA (1) UA118085C2 (hr)
WO (1) WO2013170068A2 (hr)
ZA (1) ZA202004892B (hr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
KR102022716B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
SI3404027T1 (sl) 2012-05-09 2020-08-31 Biogen Ma Inc. Modulatorji jedrnega transporta in njihova uporaba
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
EP3143627B1 (en) * 2014-05-13 2018-07-11 QSA Global Inc. Device and method for enhanced iridium gamma radiation sources
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
SG10201808624VA (en) 2014-08-15 2018-11-29 Karyopharm Therapeutics Inc Polymorphs of selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US20200216906A1 (en) * 2015-08-25 2020-07-09 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3423468A4 (en) * 2016-02-29 2019-10-23 Ohio State Innovation Foundation AZE-PEPTIDE ALDEHYDES AND KETONES
EP3429690A4 (en) 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHOD FOR MODULATING KEAP1
EP3448234A4 (en) 2016-04-30 2019-05-01 Envision Diagnostics, Inc. MEDICAL DEVICES, SYSTEMS AND METHODS FOR OPERATING OCULAR EXAMINATIONS AND OCULOMETRY
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20230110828A (ko) 2018-01-10 2023-07-25 엑스더블유파마 리미티드 케타민의 전구약물, 및 이의 조성물 및 용도
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
US20220034907A1 (en) 2018-12-06 2022-02-03 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
MA55808A (fr) * 2019-05-01 2022-03-09 Karyopharm Therapeutics Inc Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
JPWO2022209477A1 (hr) 2021-04-01 2022-10-06
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (de) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE69736775T2 (de) 1996-04-04 2007-08-23 Shionogi & Co., Ltd. Cephemverbindungen und medikamente die diese verbindungen enthalten
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
CN1227229C (zh) 1996-04-25 2005-11-16 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
RU2337682C2 (ru) 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
WO2005115990A1 (ja) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
EP1780210A4 (en) 2004-08-11 2009-06-10 Kyorin Seiyaku Kk NEW CYCLIC AMINOBENOIC ACID DERIVATIVE
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
JPWO2006088246A1 (ja) 2005-02-18 2008-07-10 武田薬品工業株式会社 Ｇｐｒ３４受容体機能調節剤
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
EP2007720B1 (en) 2006-04-07 2013-12-25 MethylGene Inc. Benzamide derivatives as inhibitors of histone deacetylase
PL2014652T3 (pl) 2006-04-18 2015-02-27 Nippon Chemiphar Co Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
WO2007147336A1 (en) 2006-06-13 2007-12-27 Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their peparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
AR063211A1 (es) 2006-07-27 2009-01-14 Amorepacific Corp Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide.
KR101404360B1 (ko) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2176228A1 (en) * 2007-07-04 2010-04-21 NeuroSearch A/S Novel pyrazole derivatives useful as potassium channel modulators
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
WO2011069039A1 (en) * 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
KR102022716B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
SI3404027T1 (sl) 2012-05-09 2020-08-31 Biogen Ma Inc. Modulatorji jedrnega transporta in njihova uporaba
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
CN105294682B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
SG10201808624VA (en) 2014-08-15 2018-11-29 Karyopharm Therapeutics Inc Polymorphs of selinexor
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
EP3404027B1 (en) 2020-03-04
EP2858991B1 (en) 2018-08-08
US10925859B2 (en) 2021-02-23
CO7190242A2 (es) 2015-02-19
SI3404027T1 (sl) 2020-08-31
CY1123476T1 (el) 2022-03-24
AU2021221398A1 (en) 2021-09-16
EA201492050A1 (ru) 2015-07-30
US20130317031A1 (en) 2013-11-28
US20160354347A1 (en) 2016-12-08
BR112014027860B8 (pt) 2024-04-30
NZ702663A (en) 2017-03-31
SG11201407268SA (en) 2015-01-29
CN104428295B (zh) 2017-08-08
US9266843B2 (en) 2016-02-23
US10722497B2 (en) 2020-07-28
ZA202004892B (en) 2023-03-29
AU2018201012A1 (en) 2018-03-01
AU2013259384A1 (en) 2014-12-18
UA118085C2 (uk) 2018-11-26
EP2858991A2 (en) 2015-04-15
PT2858991T (pt) 2018-12-17
US9861614B2 (en) 2018-01-09
KR20200041986A (ko) 2020-04-22
PL3404027T3 (pl) 2020-09-21
WO2013170068A2 (en) 2013-11-14
DK3404027T3 (da) 2020-06-02
KR102095429B1 (ko) 2020-03-31
EA036639B1 (ru) 2020-12-02
HUE040427T2 (hu) 2019-03-28
JP6195909B2 (ja) 2017-09-13
US10617677B2 (en) 2020-04-14
CL2014003054A1 (es) 2015-05-15
AU2019272017B2 (en) 2021-05-27
PT3404027T (pt) 2020-03-30
BR112014027860A2 (pt) 2017-06-27
US11318120B2 (en) 2022-05-03
JP2020037585A (ja) 2020-03-12
JP2021063104A (ja) 2021-04-22
AU2016222459A1 (en) 2016-09-22
US9096543B2 (en) 2015-08-04
KR20200115688A (ko) 2020-10-07
US20180289675A1 (en) 2018-10-11
KR20200041984A (ko) 2020-04-22
US20200230110A1 (en) 2020-07-23
LT3404027T (lt) 2020-07-10
US9585874B2 (en) 2017-03-07
AU2013259384B2 (en) 2016-06-02
DK2858991T3 (en) 2018-11-26
HUE050452T2 (hu) 2021-03-29
CN104428295A (zh) 2015-03-18
US20190008833A1 (en) 2019-01-10
ME03795B (me) 2021-04-20
AU2018201012B2 (en) 2019-12-05
WO2013170068A3 (en) 2014-02-20
CY1120832T1 (el) 2019-12-11
GEP20237477B (en) 2023-03-27
US20210251968A1 (en) 2021-08-19
HRP20181838T1 (hr) 2018-12-28
HK1209420A1 (en) 2016-04-01
PE20150128A1 (es) 2015-02-23
KR20200118240A (ko) 2020-10-14
AU2021221398B2 (en) 2023-08-17
KR102223028B1 (ko) 2021-03-03
US20160145246A1 (en) 2016-05-26
US20200038373A1 (en) 2020-02-06
JP2018172444A (ja) 2018-11-08
JP2015516434A (ja) 2015-06-11
ES2794866T3 (es) 2020-11-19
JP6818849B2 (ja) 2021-01-20
MX364992B (es) 2019-05-17
US20150111893A1 (en) 2015-04-23
JP2018012715A (ja) 2018-01-25
CA2872190A1 (en) 2013-11-14
US10335393B2 (en) 2019-07-02
PL2858991T3 (pl) 2019-01-31
KR102163377B1 (ko) 2020-10-08
EP3663291A1 (en) 2020-06-10
SI2858991T1 (sl) 2018-12-31
RS60424B1 (sr) 2020-07-31
ES2702279T3 (es) 2019-02-28
US10058535B2 (en) 2018-08-28
IN2014DN09434A (hr) 2015-07-17
RS58058B1 (sr) 2019-02-28
KR20150018809A (ko) 2015-02-24
MX2014013551A (es) 2015-01-16
KR102165177B1 (ko) 2020-10-13
EP3404027A1 (en) 2018-11-21
AU2019272017A1 (en) 2019-12-19
BR112014027860B1 (pt) 2022-03-08
US20170319551A1 (en) 2017-11-09
LT2858991T (lt) 2018-11-26

Similar Documents

Publication Publication Date Title
HRP20200876T1 (hr) Modulatori nuklearnog transporta i njihove uporabe
RU2019118390A (ru) Производное пиразоло-гетероарила, способ его получения и медицинское применение
HRP20160533T1 (hr) Indoli kao antivirusna sredstva respiratornog sincicijskog virusa
AR081653A1 (es) Inhibidores del virus de la hepatitis c
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20180483T1 (hr) Spoj kinolona
HRP20200408T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
HRP20180447T1 (hr) Derivati kinazolina za liječenje virusnih infekcija i drugih bolesti
HRP20171999T1 (hr) Novi derivati aminopirimidina
JP2016506960A5 (hr)
CL2022000125A1 (es) Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos. (divisional de solicitud 202002253)
HRP20191525T1 (hr) Inhibitori replikacije virusa influence
HRP20210942T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
RS51782B (en) AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
BR112015004529A8 (pt) alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
RS53569B1 (en) NEW COMPOUNDS AND COMPOSITIONS, AND PROCEDURES FOR USE
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2016506962A5 (hr)
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
BRPI0519287A2 (pt) derivados de amida
WO2011041713A3 (en) Piperazinyl antiviral agents
HRP20120523T1 (hr) Inhibitori virusa hepatitisa c
UY32759A (es) Inhibidores del virus de la hepatitis c